Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.70 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297762 | 0.84 | AKR1C2 (0.55) | PNMTIDO1SIGMAR1TSHRMEN1 | |
| SCHEMBL27323428 | 0.83 | GABRA1 (0.55) | PNMTGABRA1GABRB2AKR1C2AKR1C1 | |
| SCHEMBL7637108 | 0.83 | GABRA1 (0.60) | PNMTGABRA1GABRB2AKR1C2AKR1C1 | |
| SCHEMBL6126069 | 0.83 | PNMT (0.50) | PNMTGABRA1GABRB2ALDH1A1AKR1C2 | |
| SCHEMBL10019195 | 0.83 | PNMT (0.50) | PNMTSIGMAR1GABRA1GABRB2SLC6A2 | |
| SCHEMBL3058411 | 0.83 | PNMT (1.00) | PNMTTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3058413 | 0.83 | PNMT (1.00) | PNMTTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2424621 | 0.83 | PNMT (0.66) | PNMTIDO1SIGMAR1TAAR1TMEM97 | |
| SCHEMBL17413477 | 0.83 | PNMT (1.00) | PNMTTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20353176 | 0.83 | PNMT (0.66) | PNMTIDO1SIGMAR1TAAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863638-B1 | PHOSPHODIESTERASE INHIBITORS | UNIV NEBRASKA (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007038829-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2007-04-12 | — | — | WO | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| CN-1524071-A | Malononitrile compounds and their use as pesticides | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | PNMT 3998/4885IDO1 1056/4885SIGMAR1 3344/4885 |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | PNMT 3085/4885IDO1 2754/4885SIGMAR1 1833/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | PNMT 3377/4885IDO1 3700/4885SIGMAR1 4190/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | PNMT 2010/4885IDO1 2615/4885SIGMAR1 1170/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | PNMT 3593/4885IDO1 1593/4885SIGMAR1 2158/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | PNMT 1381/4885IDO1 1883/4885SIGMAR1 2609/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | PNMT 2603/4885IDO1 1079/4885SIGMAR1 3270/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | PNMT 579/4885IDO1 2389/4885SIGMAR1 3386/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | PNMT 2176/4885IDO1 3389/4885SIGMAR1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.